91精品黑料吃瓜

The University of Ottawa and The Ottawa Hospital launch new cancer immunotherapy research projects

September 22, 2020

BioCanRx, Canada鈥檚 Immunotherapy Network, today announced funding of $10M for 14 research projects and eight core and biomanufacturing facilities across the country.

91精品黑料吃瓜

BioCanRx, Canada鈥檚 Immunotherapy Network, today announced funding of . Researchers at the University of Ottawa (91精品黑料吃瓜) and The Ottawa Hospital (TOH) are playing a key role in the following seven projects:

  • Principal Investigators from 91精品黑料吃瓜/TOH: ,
  • Other Principal Investigators: (McMaster University)
  • Funding ($2,311,500, including $616,500 from BioCanRx)

  • Principal Investigators from 91精品黑料吃瓜/TOH: ,
  • Other Principal Investigators: (Carleton University)
  • Funding: $1,016,133
  • Core Resources:

  • Principal Investigators from 91精品黑料吃瓜/TOH: (also with the National Research Council of Canada),
  • Other Principal Investigators: (BC Cancer), (BC Cancer), (BC Cancer)
  • Funding: $1,540,791

  • Principal Investigators from 91精品黑料吃瓜/TOH: , ,
  • Funding: $284,955 (including $100,000 from BioCanRx)
  • Core Resources: ,

  • Principal Investigators from 91精品黑料吃瓜/TOH:
  • Funding: $190,000 (including $100,000 from BioCanRx)
  • Core Resources: ,

  • Principal Investigators from 91精品黑料吃瓜/TOH: , ,
  • Funding: $423,950
  • Core Resources: ,

  • Principal Investigators from 91精品黑料吃瓜 / The Ottawa Hospital:
  • Other Principal Investigators: (Queen鈥檚 University)
  • Funding: Total $2,834,111 (including $750,000 from BioCanRx)
  • Additional information:

鈥淲e鈥檙e collaborating and building teams across Canada to find new ways for the body鈥檚 immune system to outsmart and kill cancer,鈥 said Dr. John Bell, Scientific Director of BioCanRx, professor at 91精品黑料吃瓜 and senior scientist at The Ottawa Hospital. 鈥淭his new funding is helping to bridge the research gap between lab discoveries and clinical trials to ultimately benefit patients.鈥

BioCanRx is funded through the federal government鈥檚 Networks of Centres of Excellence Program. In addition to the $10M BioCanRx investment announced today, matching contributions of $16.5M from partners increase the total investment in Canadian translational cancer immunotherapy research and manufacturing facilities to $26.5M.

is providing matching funds for several of the projects, in the form of startup-funds for new scientists and support for such as the Ottawa Methods Centre, the Biotherapeutics Manufacturing Centre and ICES 91精品黑料吃瓜.

鈥淲e are proud to host the BioCanRx network at The Ottawa Hospital,鈥 said Dr. Duncan Stewart, professor at 91精品黑料吃瓜 and Executive Vice-President of Research at The Ottawa Hospital. 鈥淲orking together, we are providing crucial support for groundbreaking cancer immunotherapy research that could transform care and save lives. This wouldn鈥檛 be possible without the generous support of our donors, through The Ottawa Hospital Foundation.鈥